These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16368722)

  • 21. The pharmacokinetics of 12-week continuous contraceptive patch use.
    Lavelanet AF; Rybin D; White KO
    Contraception; 2017 Jun; 95(6):578-585. PubMed ID: 28285154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile.
    Creasy GW; Fisher AC; Hall N; Shangold GA
    J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Medication of the month. Evra: first contraceptive transdermal patch].
    Gaspard U
    Rev Med Liege; 2003 Nov; 58(11):709-12. PubMed ID: 14748201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra).
    Sibai BM; Odlind V; Meador ML; Shangold GA; Fisher AC; Creasy GW
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S19-26. PubMed ID: 11849632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial.
    Stewart FH; Kaunitz AM; Laguardia KD; Karvois DL; Fisher AC; Friedman AJ
    Obstet Gynecol; 2005 Jun; 105(6):1389-96. PubMed ID: 15932834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New hormonal contraceptives: a comprehensive review of the literature.
    Forinash AB; Evans SL
    Pharmacotherapy; 2003 Dec; 23(12):1573-91. PubMed ID: 14695038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.
    German P; Moorehead L; Pang P; Vimal M; Mathias A
    J Clin Pharmacol; 2014 Nov; 54(11):1290-8. PubMed ID: 24925712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transdermal hormonal contraception: benefits and risks.
    Burkman RT
    Am J Obstet Gynecol; 2007 Aug; 197(2):134.e1-6. PubMed ID: 17689623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evra contraceptive patch: risks of thromboembolism.
    Prescrire Int; 2007 Jun; 16(89):113-4. PubMed ID: 17590909
    [No Abstract]   [Full Text] [Related]  

  • 30. Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra.
    Harel Z; Riggs S; Vaz R; Flanagan P; Dunn K; Harel D
    J Pediatr Adolesc Gynecol; 2005 Apr; 18(2):85-90. PubMed ID: 15897103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.
    Vogler MA; Patterson K; Kamemoto L; Park JG; Watts H; Aweeka F; Klingman KL; Cohn SE
    J Acquir Immune Defic Syndr; 2010 Dec; 55(4):473-82. PubMed ID: 20842042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
    Schwartz JI; Liu F; Wang YH; Pramanik B; Johnson-Levonas AO; Gutierrez MJ; Lai E; Wagner JA
    Am J Ther; 2009; 16(6):487-95. PubMed ID: 19940609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A clinical study of transdermal contraceptive patch in Thai adolescence women.
    Piyasirisilp R; Taneepanichskul S
    J Med Assoc Thai; 2008 Feb; 91(2):137-41. PubMed ID: 18389975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women.
    Archer DF; Bigrigg A; Smallwood GH; Shangold GA; Creasy GW; Fisher AC
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S27-31. PubMed ID: 11849633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of estrogen-withdrawal headache with extended transdermal contraception.
    LaGuardia KD; Fisher AC; Bainbridge JD; LoCoco JM; Friedman AJ
    Fertil Steril; 2005 Jun; 83(6):1875-7. PubMed ID: 15950671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The contraceptive patch. Latest developments.
    Courtney K
    AWHONN Lifelines; 2006; 10(3):250-4. PubMed ID: 16792714
    [No Abstract]   [Full Text] [Related]  

  • 37. Ortho Evra, a new contraceptive patch.
    Sicat BL
    Pharmacotherapy; 2003 Apr; 23(4):472-80. PubMed ID: 12680477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of oral versus transdermal steroidal contraceptives on androgenic markers.
    White T; Jain JK; Stanczyk FZ
    Am J Obstet Gynecol; 2005 Jun; 192(6):2055-9. PubMed ID: 15970897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress in contraception: new technology.
    Linn ES
    Int J Fertil Womens Med; 2003; 48(4):182-91. PubMed ID: 13677551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.